ScreenerHero

CTX Captor Therapeutics Spolka Akcyjna

GPW · PL · Healthcare · Biotechnology · captortherapeutics.com
67.00PLN0.00%Mkt Cap: 107.47M $P/E: —

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap107.47M USD
Enterprise Value90.37M USD
Revenue (TTM)508.04K USD
Gross Profit814.23K USD
Net Income (TTM)-10.64M USD
Revenue/Share0.35 PLN
Last Price67.00 PLN
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees82
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLCPTRT00014
Valuation
P/E (Trailing)—
P/E (Forward)-10.44
PEG—
EV/EBITDA-8.35
EV/Revenue177.89
P/S211.53
P/B6.54
EPS (TTM)-7.87
EPS (Forward)—
52W Range
37.2057% of range89.20
52W High89.20 PLN
52W Low37.20 PLN
Profitability
Gross Margin68.99%
Oper. Margin-791.13%
EBITDA Margin0.00%
Profit Margin-901.22%
ROE-178.86%
ROA-104.93%
Growth
Revenue Growth-18.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.45M USD
CapEx (TTM)53.18K USD
FCF Margin-1220.59%
FCF Yield-5.77%
Net Debt-17.43M USD
Net Debt/EBITDA1.61
Balance Sheet
Debt/Equity0.15
Current Ratio5.41
Quick Ratio5.41
Book Value/Sh10.24 PLN
Cash/Share11.25 PLN
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 PLN
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)86.83 PLN
Upside (mean)+29.6%
Target Range67.00 PLN – 110.00 PLN
67.00+29.6% to mean110.00
# Analysts3
Ownership
Shares Out.6.33M
Float4.47M
Insiders29.31%
Institutions32.54%
Technical
SMA 5071.76 (-6.6%)
SMA 20076.84 (-12.8%)
Beta0.55
S&P 52W Chg14.58%
Avg Vol (30d)2.83K
Avg Vol (10d)2.50K
Technical Indicators
RSI (14)34.9
MACD-1.1777
MACD Signal-0.7779
MACD Hist.-0.3998
BB Upper74.99 PLN
BB Middle70.81 PLN
BB Lower66.64 PLN
BB Width11.80%
ATR (14)2.360 PLN
Vol Ratio (20d)2.23x